Semaglutide Trial Targets Young Adults with Resistant Early-Onset Obesity

The global rise in obesity is particularly concerning among adolescents, presenting a significant public health challenge. While structured lifestyle interventions are the primary treatment, a substantial portion—specifically 25%—of adolescents do not achieve meaningful weight reduction through these methods. This highlights a critical need for more effective therapeutic strategies. This study, the RESETTLE Study, aims to address this knowledge gap by investigating the efficacy of combining lifestyle interventions with the GLP-1 receptor agonist semaglutide for young adults with otherwise treatment-resistant obesity.

As the RESETTLE Study is currently recruiting participants and is projected to complete in 2026, no results are available yet. However, the study is designed to uncover several critical findings regarding the efficacy of semaglutide in a challenging patient population. The primary objective is to assess the extent of adiposity and BMI reduction in young adults with early-onset, treatment-resistant obesity when treated with semaglutide compared to placebo. Researchers anticipate a significant reduction in BMI SDS and overall body weight, alongside potential improvements in various metabolic health markers such as blood glucose levels, insulin sensitivity, and lipid profiles. The most impactful finding, if successful, would be a clinically meaningful reduction in BMI and adiposity in a population that has previously shown resistance to conventional lifestyle interventions, potentially demonstrating semaglutide's ability to overcome this treatment challenge and offer a new therapeutic avenue. Secondary outcomes will likely include changes in body composition, quality of life metrics, and the long-term safety and tolerability of semaglutide 3 mg/ml in this specific young adult cohort.